| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vestibulocochlear Nerve Diseases | D000160 | 1 associated lipids |
| Acromegaly | D000172 | 6 associated lipids |
| Actinobacillus Infections | D000189 | 4 associated lipids |
| Actinomycosis | D000196 | 2 associated lipids |
| Addison Disease | D000224 | 3 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Albuminuria | D000419 | 18 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Angina, Unstable | D000789 | 14 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ferrari SL et al. | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. | 2005 | Endocrinology | pmid:15705780 |
| Heymann D et al. | Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. | 2005 | Drug Discov. Today | pmid:15708742 |
| Mezquita-Raya P et al. | The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. | 2005 | Osteoporos Int | pmid:15711777 |
| Pantouli E et al. | Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15721297 |
| Korcok J et al. | P2Y6 nucleotide receptors activate NF-kappaB and increase survival of osteoclasts. | 2005 | J. Biol. Chem. | pmid:15722352 |
| Bock O et al. | Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. | 2005 | J. Pathol. | pmid:15726648 |
| Mosheimer BA et al. | Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. | 2005 | J. Clin. Endocrinol. Metab. | pmid:15728209 |
| Han KO et al. | The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone. | 2005 | Clin. Endocrinol. (Oxf) | pmid:15730418 |
| Xiao XH et al. | [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15730627 |
| Tiranathanagul S et al. | Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. | 2004 | J. Periodontol. | pmid:15732867 |
| Schneider HG and Sentry J | Multiple myeloma. | 2005 | N. Engl. J. Med. | pmid:15736296 |
| Ambroszkiewicz J et al. | [Biochemical bone resorption markers in children with osteosarcoma]. | 2004 Apr-Jun | Med Wieku Rozwoj | pmid:15738598 |
| Skládal P et al. | Investigation of osteoprotegerin interactions with ligands and antibodies using piezoelectric biosensors. | 2005 | Biosens Bioelectron | pmid:15741072 |
| Kanno T et al. | Platelet-rich plasma enhances human osteoblast-like cell proliferation and differentiation. | 2005 | J. Oral Maxillofac. Surg. | pmid:15742288 |
| Mazziotti G et al. | Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. | 2005 | J. Bone Miner. Res. | pmid:15746993 |
| Corey E et al. | Osteoprotegerin in prostate cancer bone metastasis. | 2005 | Cancer Res. | pmid:15753366 |
| Moschen AR et al. | The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. | 2005 | Gut | pmid:15753532 |
| Nagasaki T et al. | Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. | 2005 | Eur. J. Endocrinol. | pmid:15757850 |
| Kostenuik PJ | Revisiting the seed and soil theory of bone metastasis: new tools, same answer. | 2004 | J Musculoskelet Neuronal Interact | pmid:15758267 |
| Simmons CA et al. | Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. | 2005 | Circ. Res. | pmid:15761200 |
| Gallant MA et al. | Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. | 2005 | J. Bone Miner. Res. | pmid:15765187 |
| Mandelin J et al. | Pseudosynovial fluid from loosened total hip prosthesis induces osteoclast formation. | 2005 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15768436 |
| Crisafulli A et al. | Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. | 2005 | Menopause | pmid:15772566 |
| Mizuno N et al. | Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. | 2005 | Cell Biol. Int. | pmid:15774307 |
| Indridason OS et al. | Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. | 2005 | Osteoporos Int | pmid:15776220 |
| Voskaridou E and Terpos E | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. | 2005 | Eur. J. Haematol. | pmid:15777350 |
| Mossetti G et al. | Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment. | 2005 | Bone | pmid:15777635 |
| Janssens K et al. | An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation. | 2005 | Bone | pmid:15777670 |
| Fábrega E et al. | Osteoprotegerin and RANKL in alcoholic liver cirrhosis. | 2005 | Liver Int. | pmid:15780054 |
| Fukushima H et al. | IL-1-induced receptor activator of NF-kappa B ligand in human periodontal ligament cells involves ERK-dependent PGE2 production. | 2005 | Bone | pmid:15780952 |
| Regmi A et al. | Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation. | 2005 | Bone | pmid:15780954 |
| Abrahamsen B et al. | Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. | 2005 | Bone | pmid:15781001 |
| Zhao HY et al. | The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women. | 2005 | Osteoporos Int | pmid:15782282 |
| Bezerra MC et al. | RANK, RANKL and osteoprotegerin in arthritic bone loss. | 2005 | Braz. J. Med. Biol. Res. | pmid:15785827 |
| Stilgren LS et al. | [The cytokine system of bone tissue]. | 2005 | Ugeskr. Laeg. | pmid:15789838 |
| Fukushima H et al. | Parathyroid-hormone-related protein induces expression of receptor activator of NF-{kappa}B ligand in human periodontal ligament cells via a cAMP/protein kinase A-independent pathway. | 2005 | J. Dent. Res. | pmid:15790738 |
| Konduri K et al. | Immunoglobulin M myeloma: evaluation of molecular features and cytokine expression. | 2005 | Clin Lymphoma | pmid:15794867 |
| Bord S et al. | Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL. | 2005 | Bone | pmid:15794927 |
| Giuliani N et al. | Update on the pathogenesis of osteolysis in multiple myeloma patients. | 2004 | Acta Biomed | pmid:15796087 |
| Contractor T et al. | Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin. | 2005 Mar-Apr | In Vivo | pmid:15796195 |
| Zannettino AC et al. | Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. | 2005 | J. Cell. Physiol. | pmid:15799029 |
| Tada T et al. | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. | 2005 | Int. J. Cancer | pmid:15800904 |
| Mandelin J et al. | Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. | 2005 | J. Rheumatol. | pmid:15801030 |
| Holmen SL et al. | Essential role of beta-catenin in postnatal bone acquisition. | 2005 | J. Biol. Chem. | pmid:15802266 |
| Bernstein CN et al. | Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. | 2005 | Inflamm. Bowel Dis. | pmid:15803021 |
| Mitani M et al. | Estrogen specifically stimulates expression and production of osteoprotegerin from rheumatoid synovial fibroblasts. | 2005 | Int. J. Mol. Med. | pmid:15806305 |
| Ling LJ et al. | Areca nut extracts modulated expression of alkaline phosphatase and receptor activator of nuclear factor kappaB ligand in osteoblasts. | 2005 | J. Clin. Periodontol. | pmid:15811051 |
| Maïmoun L et al. | Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury. | 2005 | Calcif. Tissue Int. | pmid:15812577 |
| Ulrich-Vinther M and Andreassen TT | Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. | 2005 | Calcif. Tissue Int. | pmid:15812581 |
| Ishizuka K et al. | Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol. | 2005 | Neurosci. Lett. | pmid:15814197 |
| Cui N et al. | Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. | 2005 | Clin. Cancer Res. | pmid:15814653 |
| Gorczynski RM et al. | Neutral buoyancy and sleep-deprived serum factors alter expression of cytokines regulating osteogenesis. | 2005 May-Jun | Acta Astronaut | pmid:15835039 |
| Essalihi R et al. | Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? | 2004 | J. Cardiovasc. Pharmacol. | pmid:15838266 |
| Morony S et al. | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | 2005 | Endocrinology | pmid:15845617 |
| Rhee EJ et al. | The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. | 2005 | Am. J. Obstet. Gynecol. | pmid:15846185 |
| Mahamed DA et al. | G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. | 2005 | Diabetes | pmid:15855336 |
| Leder BZ and Finkelstein JS | Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. | 2005 | Osteoporos Int | pmid:15856361 |
| Galli C et al. | Comparison of human mandibular osteoblasts grown on two commercially available titanium implant surfaces. | 2005 | J. Periodontol. | pmid:15857069 |
| Suzuki K et al. | Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. | 2005 | Diabetes Res. Clin. Pract. | pmid:15860239 |
| Glass DA et al. | Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. | 2005 | Dev. Cell | pmid:15866165 |
| Valenta A et al. | Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. | 2005 | Bone | pmid:15869920 |
| Chan MH et al. | Specific biochemical markers of bone metabolism and cytokine study confirm the diagnosis of malignant infantile osteopetrosis at birth using cord blood sample. | 2005 | Pathology | pmid:15875734 |
| Seminari E et al. | Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. | 2005 | HIV Med. | pmid:15876279 |
| Schett G et al. | Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. | 2005 | Arthritis Rheum. | pmid:15880601 |
| Moe SM et al. | Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). | 2005 | Kidney Int. | pmid:15882271 |
| Ueland T et al. | Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. | 2005 | Circulation | pmid:15883214 |
| Sabokbar A et al. | Arthroplasty membrane-derived fibroblasts directly induce osteoclast formation and osteolysis in aseptic loosening. | 2005 | J. Orthop. Res. | pmid:15885469 |
| Skoumal M et al. | Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. | 2005 | Rheumatol. Int. | pmid:15889303 |
| Inoue H et al. | Prostate cancer mediates osteoclastogenesis through two different pathways. | 2005 | Cancer Lett. | pmid:15890244 |
| Lynch CC et al. | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | 2005 | Cancer Cell | pmid:15894268 |
| Choi BK et al. | Prostaglandin E(2) is a main mediator in receptor activator of nuclear factor-kappaB ligand-dependent osteoclastogenesis induced by Porphyromonas gingivalis, Treponema denticola, and Treponema socranskii. | 2005 | J. Periodontol. | pmid:15898943 |
| Carda C et al. | Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint. | 2005 | Tissue Cell | pmid:15899507 |
| Chang K et al. | Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor. | 2005 | J. Orthop. Res. | pmid:15913941 |
| Depil S et al. | Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma. | 2005 | Br. J. Haematol. | pmid:15916694 |
| Rasmussen LM and Ledet T | Osteoprotegerin and diabetic macroangiopathy. | 2005 | Horm. Metab. Res. | pmid:15918117 |
| Tanabe N et al. | IL-1 alpha stimulates the formation of osteoclast-like cells by increasing M-CSF and PGE2 production and decreasing OPG production by osteoblasts. | 2005 | Life Sci. | pmid:15921993 |
| Crisafulli A et al. | Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. | 2005 | Clin. Sci. | pmid:15926884 |
| Koh JM et al. | Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells. | 2005 | J. Endocrinol. | pmid:15930166 |
| Bhattacharya A et al. | Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids. | 2005 | J Am Coll Nutr | pmid:15930486 |
| Buemi M et al. | Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration. | 2005 Mar-Apr | J. Nephrol. | pmid:15931642 |
| Kerschan-Schindl K et al. | Serum levels of cathepsin K decrease with age in both women and men. | 2005 | Exp. Gerontol. | pmid:15935595 |
| Ugur-Altun B et al. | The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. | 2005 | Diabetes Res. Clin. Pract. | pmid:15936463 |
| Moran CS et al. | Association of osteoprotegerin with human abdominal aortic aneurysm progression. | 2005 | Circulation | pmid:15939823 |
| Li F et al. | Annexin II stimulates RANKL expression through MAPK. | 2005 | J. Bone Miner. Res. | pmid:15940368 |
| Sen O et al. | The relation between serum levels of osteoprotegerin and postoperative epidural fibrosis in patients who underwent surgery for lumbar disc herniation. | 2005 | Neurol. Res. | pmid:15949247 |
| Saunders MM et al. | Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells. | 2006 | J Biomech | pmid:15953606 |
| Liu JZ et al. | [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15969033 |
| Liu JZ et al. | [The OPG/RANKL/RANK system and bone resorptive disease]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15971575 |
| Frick KK et al. | RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro. | 2005 | Am. J. Physiol. Renal Physiol. | pmid:15972386 |
| Lossdörfer S et al. | PTH(1-34) affects osteoprotegerin production in human PDL cells in vitro. | 2005 | J. Dent. Res. | pmid:15972592 |
| Arko B et al. | Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. | 2005 | Maturitas | pmid:15978970 |
| Bock O et al. | Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. | 2005 | Br. J. Haematol. | pmid:15982347 |
| Fiore CE et al. | Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. | 2005 | Osteoporos Int | pmid:15983730 |
| Amizuka N et al. | Histological evaluation for "bone quality" on two mouse models with different bone remodeling. | 2005 | J. Bone Miner. Metab. | pmid:15984413 |
| Ziegler S et al. | Endurance running acutely raises plasma osteoprotegerin and lowers plasma receptor activator of nuclear factor kappa B ligand. | 2005 | Metab. Clin. Exp. | pmid:15988704 |
| Yamada N et al. | Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. | 2005 | Cytokine | pmid:15996478 |
| Quinn JE et al. | Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. | 2005 | Prostate Cancer Prostatic Dis. | pmid:15999121 |
| Mangashetti LS et al. | IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kappa B and Ca2+ signaling. | 2005 | J. Immunol. | pmid:16002690 |
| Whang PG et al. | The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. | 2005 | J. Orthop. Res. | pmid:16005175 |
| Bashir A et al. | Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. | 2005 | Steroids | pmid:16005483 |